Ypsomed Holding AG/Fr. YPSN
1D1W1MYTD1Y5YMAX
Capital at risk
About Ypsomed Holding AG
Ypsomed Holding AG is a Swiss company specializing in the development and manufacturing of injection and infusion systems for self-medication, primarily serving the pharmaceuticals and biotechnology industries. Its key products include insulin pens, autoinjectors, infusion sets, and digital health solutions, catering to therapy areas such as diabetes management. Founded in 1984, the company is headquartered in Burgdorf, Switzerland, and operates globally with subsidiaries and distributors across Europe, North America, and Asia-Pacific regions. Ypsomed leverages its expertise in precision injection technology and its strategic partnerships with leading drug manufacturers to maintain its competitive position in the medical technology sector.
- Ticker
- Fr. YPSN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 2,025
- Headquarters
- Burgdorf, Switzerland
- Website
- www.ypsomed.com
YPSN Metrics
BasicAdvanced
CHF 4.7B
21.84
CHF 16.30
0.74
CHF 4.40
0.76%
Price and volume
Market cap
CHF 4.7B
Beta
0.74
52-week high
CHF 419.50
52-week low
CHF 260.50
Average daily volume
15K
Dividend rate
CHF 4.40
Financial strength
Current ratio
1.069
Quick ratio
0.735
Long term debt to equity
0.149
Total debt to equity
0.349
Dividend payout ratio (TTM)
13.53%
Interest coverage (TTM)
83.19%
Profitability
EBITDA (TTM)
325.791
Gross margin (TTM)
43.04%
Net profit margin (TTM)
30.36%
Operating margin (TTM)
36.20%
Effective tax rate (TTM)
7.90%
Revenue per employee (TTM)
CHF 360,000
Management effectiveness
Return on assets (TTM)
12.36%
Return on equity (TTM)
31.09%
Valuation
Price to earnings (TTM)
21.84
Price to revenue (TTM)
6.627
Price to book
6.27
Price to tangible book (TTM)
6.38
Price to free cash flow (TTM)
-296.397
Free cash flow yield (TTM)
-0.34%
Free cash flow per share (TTM)
-1.201
Dividend yield (TTM)
1.24%
Forward dividend yield
0.76%
Growth
Revenue change (TTM)
-2.39%
Earnings per share change (TTM)
154.29%
3-year revenue growth (CAGR)
13.69%
10-year revenue growth (CAGR)
8.05%
3-year earnings per share growth (CAGR)
62.20%
10-year earnings per share growth (CAGR)
19.11%
3-year dividend per share growth (CAGR)
50.14%
10-year dividend per share growth (CAGR)
15.97%
Bulls say / Bears say
The core Delivery Systems business grew revenue 20% to CHF 601.5 million, with EBIT rising to CHF 195.5 million and an approximately 33% margin; commercial autoinjector sales increased 33.6%. (Ypsomed)
Ypsomed secured a record number of customer projects, launched three product platforms, and guided to 12%–15% sales growth and CHF 210–230 million EBIT in FY2026/27 for continuing Delivery Systems. (Ypsomed)
The planned Holly Springs, North Carolina facility should expand U.S. capacity, improve customer proximity and supply security, and support local production from the end of 2027. (Ypsomed)
Group revenue fell to CHF 731.0 million in FY2025/26 from CHF 748.9 million, while the more-than-doubling of EBIT was partly driven by a disposal gain, making reported earnings quality less clean. (Ypsomed)
Ypsomed is phasing out Delivery Systems contract manufacturing, reducing continuing-business like-for-like revenue to approximately CHF 559 million from CHF 601.5 million reported in FY2025/26 and creating a transition burden for near-term growth. (Ypsomed)
Valuation and execution remain material risks: Jefferies initiated coverage with an Underperform rating and a CHF 280 price target, citing doubts about Ypsomed’s ability to meet its medium-term targets. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Upcoming events
No upcoming events
Funds containing YPSN
AllEURGBPUSD
Fund name | Fund size | Fr. YPSN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.11% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.11% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.